AnaptysBio recently announced that the Delaware Chancery Court dismissed Tesaro’s anticipatory breach of contract claim, rejecting Tesaro’s bid to reduce Jemperli royalties and affirming that ...

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB) been one of those stocks this year?

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects low ...

Wall Street expects a year-over-year increase in earnings on lower revenues when AnaptysBio, Inc. (ANAB) reports results for ...

Multiple analysts have issued price targets for $ANAB recently. We have seen 6 analysts offer price targets for $ANAB in the last 6 months, with a median target of ...

Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune ...

On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial ...